Financings in Brief: Gelman Sciences
This article was originally published in The Gray Sheet
Executive Summary
Gelman Sciences: Files registration statement with the Securities and Exchange Commission for an offering of 1 mil. shares of common stock. The microfiltration products firm plans to use proceeds to repay a term note it owes NBD Bank, as well as to pay down debt from "credit arrangements" with NBD and Comerica Bank. Stock in Gelman has been trading in the $13-15 per share range. The issue, which trades on the American Stock Exchange, was the leading percentage gainer on The Gray Sheet's "M-D-D-I" Index in 1994, gaining 5 points (51%) during the year ("The Gray Sheet" Jan. 9, p. 9). Cleary Gull Reiland & McDevitt, McDonald & Company Securities, and Roney & Co. are underwriting.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.